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Chapter 23 
ACUTE MUSCULOSKELETAL SPORTS 
INJURY AND TOPICAL NSAID 
Amit M. Deokar*, Shawn J. Smith and Hatim A. Omar 
Department of Pediatrics, Division of Adolescent Medicine, 
University of Kentucky, Lexington, Kentucky, United States. 
ABSTRACT 
The objective of this chapter is to summarize the current standards of pain 
management in minor sports related musculoskeletal injuries. We also address the topical 
form of non-steroidal anti-inflammatory drug as an effective pain management option in 
an out-patient setting. Design: Quantitive systematic review of randomized controlled 
trials. Methods: The data was obtained through literature review of articles published in 
the last 10 years. In addition, FDA information on non-steroidal anti-inflammatory 
medications was also reviewed. The patient population studied in the articles included 
children and adults. Conclusion: Current standards of managing pain resulting from 
sports injuries involve a number of analgesic drugs including non-steroidal anti-
inflammatory drugs. The topical form of this class of drugs is an effective method for 
pain management of minor musculoskeletal sports-related injuries. 
INTRODUCTION 
When compared to the 1970's, there has been increased participation in sports activities. 
Despite an increased awareness of safety measures, the participants are still at an increased 
risk from sports-related injuries [1]. Various agencies are involved in the surveillance and 
epidemiologic data on sports-related injuries. National Health Interview Survey is one such 
agency that collects data for the National Center for Health Statistics (NCHS) [2]. 
Musculoskeletal injuries are one of the primary reasons that patients seek medical attention in 
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the out-patient family practice setting [3]. Throughout the United States, a large portion of 
emergency department (ED) visits is following acute sports-related injuries [4]. 
Approximately 3.7 million sports-related injuries occur in people of all ages and each year 
about 2.5 million ED visits resulting from sports injuries occur in the pediatric population [4]. 
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) for pain from 
musculoskeletal injuries is well known and extensive [3]. Musculoskeletal injuries include 
injuries to muscle, ligaments, tendons, and non-fracture injuries. Treatment of such injuries is 
generally geared toward reducing the swelling and pain by using methods such as cold 
compression and an anti-inflammatory agent [5]. Typically, the use ofNSAIDs is due to their 
anti-inflammatory, analgesic, and anti-pyretic properties. The basis of the pharmacological 
action ofNSAIDs is their ability to inhibit cylooxygenase (COX) enzymes thereby blocking 
the formation of certain prostaglandins (PGs). Besides reducing the inflammation, this 
inhibition of PG synthesis may potentially result in serious side effects such as 
gastrointestinal disturbance and altered renal function [3,6]. Cyclooxygenase-2 (COX-2) 
inhibitors such as Rofecoxib (Vioxx™) were popular analgesics especially in the last decade. 
This was because they do not inhibit the beneficial effects of PG's, and thus have fewer side 
effects on the gastric mucosal lining. They also do not affect bleeding time and platelet 
function [6]. Because of serious cardiovascular side effects reported with the use of COX-2 
inhibitors, some of these products were withdrawn from the US markets in 2004 [7]. 
Due to non-availability of topical form of analgesics in the US market, and because of the 
negative side effects from a systemic non-steroidal anti-inflammatory drug, an alternative 
delivery method such as topical can be utilized. A topical route ofNSAIDs has the benefit of 
superior local drug delivery. At the same time the systemic side effects that may arise from 
oral NSAIDs are reduced by using the topical route [5]. A sufficiently high concentration of 
the drug is necessary to penetrate the skin, muscles, and synovial fluid and this is seen when 
an NSAID is topically administered. In addition to this benefit, the topical form also allows a 
constant and slow release of the drug [ 5]. 
We conducted a literature search using PubMed and included terms such as "topical 
NSAIDs", "oral NSAIDs", "sports injuries", "musculoskeletal injuries", and "pain 
management." 
Through the synopsis of articles below, this review attempts to emphasize the 
effectiveness ofNSAIDs on pain from acute musculoskeletal sports injuries. It also addresses 
the use of a topical route as an effective and safe method for NSAID delivery. 
DISCUSSION 
Sports-related injuries that involve the ligaments, muscle, tendons, and bones are fairly 
common in sports activities. Some studies indicated that there has been a considerable 
increase in such injuries due to an increased involvement in sports activities [1 ,4]. 
Non-steroidal anti-inflammatory drugs are used frequently in pain management of 
musculoskeletal sports injuries [5]. In a randomized controlled trial (RCT) done in an ED 
setting on patients 6-17 years, who had sustained a musculoskeletal sports injury, an oral non-
steroidal, Ibuprofen, was compared with Acetaminophen and Codeine [8] . Patients in the 
Ibuprofen group showed significant improvement compared to the other two groups, as 
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demonstrated on the Visual Analog Scale (VAS). There was twice as much decrease in pain 
(24mm versus 12mm or 11 mm) on this scale (p<O.OOl) . The effectiveness ofNSAIDs is due 
to their mechanism of action that causes inhibition of prostaglandins at the injury site. Oral 
NSAIDs, when administered in such a situation achieve a relatively higher drug level 
systemically [3,6]. Although this may result in relief of pain symptoms, it may potentially 
lead to serious side effects such those on gastro protection and renal function. They may also 
interfere with coagulation mechanisms [9]. 
There are various routes by which NSAIDs can be delivered. One option is to use the 
topical route. Topical NSAID's when applied to an inflamed area results .inlocal drug 
delivery and fewer systemic side effects from high plasma drug levels. One multicenter 
controlled clinical trial published in the year 2000 compared the effectiver1~ss of the topical 
Diclofenac Sodium patch to a placebo in patients who had sustained a sports-related injury. 
Out of the two weeks of treatment, the daily pain relief on days 3, 7, and 14 wassuperior in 
the Diclofenac group (p=0.044). Another double blinded RCT conducted in .Emope<;ompared 
the Diclofenac patch to a placebo patch, reported significant (p<O.OOOl) paill relief in adult 
patients who sustained an acute impact sports injury and those who received the active drug 
[5]. This study also reaffim1ed the safety and reduced systemic side effep~sfrplll. llse of a 
topical form of an NSAID. Local side effects such as rash or itch occurred si!llilarly in both 
active as well as inactive patch [5]. Another study (randomized double blinded, placebo-
controlled) conducted in Europe concluded the efficacy of topical Ketoprofenconw~~ed to a 
placebo in patients who had a benign ankle sprain. This topical NSAID was alsotolerated 
well, with only local side effects [ 1 0]. Recently, a prospective, randomized, open study 
compared two topical agents, Ketoprofen and Diclofenac gel in patients who sustained an 
acute, benign, sports-related injury. The efficacy of transdermal (TDS) Ketoprofen in 
relieving pain was comparable to the Diclofenac gel. The TDS Ketoprofen wasfound to be 
superior to the Diclofenac gel (64% versus 46%, p=0.004) leading to a high cure rate on day 7 
of the treatment [11]. 
Despite growing evidence that suppotis the effectiveness of topical NSAID's in pain 
relief and minimizing the systemic adverse events, several limitations exist forthe type of 
studies conducted thus far in this area. For example, the randomized controlled clinical trials 
have compared a placebo over a topical form of NSAID to examine the effectiveness and 
safety profile. While placebo controlled studies are usually preferred to compare the 
effectiveness of a new drug, it may affect the standard of care for some of the patients. In 
addition, not many studies have been done exclusively in the pediatric population. Data from 
the studies done in adults may help researchers conduct clinical trials in children. 
Topical Diclofenac Sodium formulation is available for use in Europe and other countries 
[5]. In the United States, Dicofenac is available as an oral as well as a topical form. The 
topical application is a 3% gel that was FDA-approved for Actinic Keratosis in 2002. As of 
October 2007, the topical Diclofenac Sodium patch was in its Phase 1 clinical study, which is 
being conducted by Cerimon Pharmaceuticals [12]. Numerous clinical trials in the United 
States are currently undergoing that are looking at the use of topical NSAID for breast pain 
and osteoarthritis [13]. The efficacy of topical non-steroidal anti-inflammatory drugs over a 
placebo has been noted in various trials involving acute sprain injury as well as chronic 
conditions such as rheumatoid arthritis [14]. Once approved, the topical form of anti-
inflammatory drugs is likely to revolutionize the standard of care in pain management of 
acute benign sports-related musculoskeletal injuries. The use of topical non-steroidal drugs 
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for chronic pain will also be of particular advantage in the elderly population due to their 
safety profile (14). 
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